The Online Investor
TetraLogic Pharmaceuticals Corp (TLOG)

TetraLogic Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. Co. has two clinical-stage product candidates in development: birinapant and suberohydroxamic acid 4-methoxycarbonyl phenyl ester (SHAPE). SHAPE is Co.'s proprietary histone deacetylase inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases, which causes apoptosis, or cell-death, in damaged cells.
Company Name: 
TetraLogic Pharmaceuticals Corp
Drugs & Pharmaceuticals
Quotes delayed 20 minutes

Email EnvelopeFree TLOG Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (4.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

TetraLogic Pharmaceuticals Corp (TLOG) Page | The Online Investor Page |

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.